Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2183-2187

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Tsigkas, Grigorios ^a   Damelou, Anastasia ^a   Theodoropoulos, Konstantinos C ^a   Kassimis, George ^a   Chouchoulis, Konstantinos ^a   Davlouros, Periklis ^a   Chiladakis, John ^a   Hahalis, George ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Acute myocardial infarction; Antiplatelet agents; Clopidogrel; Platelet function inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN; HEPARIN; PANTOPRAZOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEMATOCRIT; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; IMPLANTATION; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84865488153     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0173     Document Type: Article

References (37)

1. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009; 373: 723-731.
2. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141.
3. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. J Am Coll Cardiol 2010; 56: 1542-1551.
4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the ef fect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
5. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Bañuelos C, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910.
7. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
8. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the strategy study. J Am Coll Cardiol 2006; 48: 2178-2185.
9. Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2006; 122: 776-781.
10. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
11. Schäfer A, Flierl U, Kössler J, Seydelmann N, Kobsar A, Störk S, et al. Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. Thromb Haemost 2011; 106: 141-148.
12. Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res 2010; 125: e190-e196.
13. Cuisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009; 123: 597-603.
14. Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359-1367.
15. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than highdose (150-mg) clopidogrel: The importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4: 403-410.
16. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 5615: 919-933.
17. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.
18. Barros AJ, Hirakata VN. Alternatives for logistic regression in crosssectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3: 21.
19. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-2564.
20. Vavuranakis M, Vrachatis DA, Papaioannou TG, Archontakis S, Kalogeras KI, Kariori MG, et al. Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. Circ J 2011; 75: 2105-2112.
21. Larson DM, Duval S, Sharkey SS, Solie C, Tschautscher C, Lips DL, et al. Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. Am Heart J 2010; 160: 202-207.
22. Dörler J, Edlinger M, Alber HF, Altenberger J, Benzer W, Grimm G, et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32: 2954-2961.
23. Koul S, Smith JG, Schersten F, James S, Lagerqvist B, Erlinge D. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011; 32: 2989-2997.
24. Vlaar PJ, Svilaas T, Damman K, de Smet BJ, Tijssen JG, Hillege HL, et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review. Circulation 2008; 118: 1828-1836.
25. Alexander D, Mann N, Ou FS, Peterson ED, Ohman EM, Gibler WB, et al. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Am J Cardiol 2008; 102: 1335-1340.
26. Zeymer U, Arntz HR, Darius H, Huber K, Senges J. Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): Study rationale and design. Cardiology 2007; 108: 265-272.
27. Pöss J, Jacobshagen C, Ukena C, Böhm M. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010; 99: 411-417.
28. Park S, Kim W, Park C, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295.
29. Angiolillo D, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.
30. Alexopoulos D, Xanthopoulou I, Panagiotou A, Komninakis D, Germanos N, Goudas P, et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am J Kidney Dis 2012; 59: 469-471.
31. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57: 399-408.
32. Cuisset T, Frere C, Moro PJ, Quilici J, Pons C, Gaborit B, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome. Thromb Res 2010; 126: e400-e402.
33. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067.
34. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052-1059.
35. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103: 1339-1343.
36. Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434.
37. Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166.